NVCR:NGS-NovoCure Limited (USD)

EQUITY | Medical Devices | Nasdaq Global Select

Last Closing

USD 16.49

Change

0.00 (0.00)%

Market Cap

USD 0.81B

Volume

0.99M

Analyst Target

USD 79.57
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NovoCure Ltd is a commercial stage oncology company. It is engaged in the development, manufacture and commercialization of tumor treating fields for the treatment of solid tumors.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-06 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

+6.15 (+10.13%)

USD 23.46B
PODD Insulet Corporation

+17.68 (+7.16%)

USD 17.22B
MASI Masimo Corporation

+19.51 (+13.45%)

USD 7.80B
BRKR Bruker Corporation

+4.83 (+13.28%)

USD 5.53B
IRTC iRhythm Technologies Inc

+6.61 (+6.83%)

USD 3.28B
PRCT Procept Biorobotics Corp

+5.86 (+12.00%)

USD 3.27B
QDEL Quidel Corporation

+2.65 (+10.11%)

USD 2.42B
TMDX TransMedics Group Inc

+7.46 (+10.98%)

USD 2.27B
LIVN LivaNova PLC

+1.87 (+5.52%)

USD 1.95B
UFPT UFP Technologies Inc

+18.71 (+9.68%)

USD 1.62B

ETFs Containing NVCR

DWAQ 0.00 % 0.60 %

N/A

N/A
NIFE 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -44.66% 21% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -44.66% 21% F 17% F
Trailing 12 Months  
Capital Gain 20.01% 89% A- 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.01% 89% A- 85% B
Trailing 5 Years  
Capital Gain -74.45% 34% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -74.45% 34% F 16% F
Average Annual (5 Year Horizon)  
Capital Gain -8.03% 37% F 25% F
Dividend Return -8.03% 37% F 24% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 79.07% 41% F 25% F
Risk Adjusted Return -10.16% 39% F 30% F
Market Capitalization 0.81B 92% A 79% B-

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 1,480.87 2% 0%
Price/Book Ratio 5.03 31% 23%
Price / Cash Flow Ratio -68.74 96% 96%
Price/Free Cash Flow Ratio -6.92 80% 88%
Management Effectiveness  
Return on Equity -46.67% 59% 33%
Return on Invested Capital -21.36% 56% 34%
Return on Assets -8.77% 66% 36%
Debt to Equity Ratio 27.01% 61% 53%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector